Cohort B (n=662) | Cohort H (n=629) | P value | |
Age, mean (SD), years | 65.6±12.9 | 64.6±13.3 | 0.15 |
Body mass index, mean (SD) | 28.6±21.7 | 28.5±17.3 | 0.93 |
Male gender, n (%) | 473 (71.5%) | 483 (76.8%) | 0.03 |
Medical history, n (%) | |||
Coronary artery disease | 152 (23.0%) | 134 (21.3%) | 0.47 |
Myocardial infarction | 113 (17.1%) | 92 (14.6%) | 0.23 |
CABG | 23 (3.5%) | 20 (3.2%) | 0.77 |
Coronary revascularisation | 88 (13.3%) | 74 (11.8%) | 0.41 |
Stroke/TIA >1 year | 29 (4.4%) | 16 (2.5%) | 0.07 |
Peripheral arterial disease | 31 (4.7%) | 25 (4.0%) | 0.21 |
Congestive heart failure | 6 (0.9%) | 7 (1.1%) | 0.71 |
Hypertension | 354 (53.5%) | 303 (48.2%) | 0.06 |
Hypercholesterolaemia | 307 (46.4%) | 294 (46.7%) | 0.90 |
Diabetes | 101 (15.3%) | 83 (13.2%) | 0.29 |
Current smoker | 216 (32.6%) | 248 (39.4%) | 0.01 |
Long-term antiplatelet therapy, n (%) | |||
Aspirin | 256 (38.7%) | 243 (38.6%) | 0.99 |
EKG presentation, n (%) | |||
ST elevation | 640 (96.7%) | 608 (96.7%) | 0.99 |
LBBB | 10 (1.5%) | 7 (1.1%) | 0.53 |
EKG territory of infarction, n (%) | |||
Anterior | 223 (33.7%) | 229 (36.4%) | 0.31 |
Cardiogenic shock, n (%) | 82 (12.4%) | 77 (12.2%) | 0.94 |
Ventilated patients, n (%) | 59 (8.9%) | 57 (9.1%) | 0.93 |
Out-of-hospital cardiac arrest, n (%) | 69 (10.4%) | 66 (10.5%) | 0.97 |
Anticoagulation, n (%) | |||
Bivalirudin | 498 (75.2%) | 5 (0.8%) | <0.01 |
Heparin | 164 (24.8%) | 624 (99.2%) | <0.01 |
Recent lysis, n (%) | 1 (0.2%) | 0 (0%) | |
Gp2b3a agent, n (%) | 154 (22.3%) | 177 (28.1%) | 0.05 |
Tirofiban | 38 (5.7%) | 22 (3.5%) | 0.06 |
Abciximab | 116 (17.5%) | 155 (24.6%) | <0.01 |
Loading dose of antiplatelet, n (%) | 633 (95.6%) | 611 (97.1%) | 0.15 |
Antiplatelet therapy received between randomisation and discharge, n (%) | |||
Aspirin | 652 (98.5%) | 617 (98.1%) | 0.58 |
Oral P2Y12 blocker, n (%) | |||
Clopidogrel | 134 (20.2%) | 75 (11.9%) | <0.01 |
Prasugrel | 411 (62.1%) | 362 (57.6%) | 0.10 |
Ticagrelor | 117 (17.7%) | 192 (30.5%) | <0.01 |
CABG, coronary artery bypass graft; Gp2b3a, glycoprotein 2b3a; LBBB, left bundle branch block.; TIA, transient ischaemic attack.